Peitzman, Steven J. published the artcileTicrynafen and probenecid in hyperuricemic, hypertensive men, Safety of 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is uricosuria hypertension ticrynafen probenecid; hyperuricemia ticrynafen probenecid.
In a double-blind crossover study of ticrynafen (I) and probenecid (II) [57-66-9], hypertensive, hyperuricemic men completed 12-wk courses of each drug. With a I dose of 125 mg daily, the fall in serum uric acid [69-93-2] was prompt, dramatic, and lasting; it was equal to that after II, 500 or 1000 mg daily. There was a small but significant early weight loss (diuresis) after I but no antihypertensive effect. Twelve days after resuming I for a proposed addnl. extension study 1 patient had acute, reversible bilateral ureteral obstruction, probably caused by sudden urinary uric acid precipitation
Clinical Pharmacology & Therapeutics (St. Louis, MO, United States) published new progress about Hypertension. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Safety of 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem